Merck has announced that the European Commission has granted marketing authorisation for Ogsiveo (nirogacestat) as ...

The oral gamma secretase inhibitor is approved as a single agent for adults with progressing desmoid tumours requiring ...

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid ...

The European Commission (EC) granted marketing authorization for Ogsiveo (nirogacestat), an oral gamma secretase inhibitor, ...

Stamford: SpringWorks Therapeutics, Inc., a healthcare company of Merck, has received marketing authorization from the ...

Merck KGaA's recently acquired SpringWorks unit has claimed EU approval for Ogsiveo, becoming the first approved therapy for ...

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumorsSTAMFORD, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., ...

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumorsSTAMFORD, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., ...

Evercore ISI initiated coverage of Immunome (IMNM) with an Outperform rating and $18 price target The company is developing a deep ADC pipeline ...

One of Ogsiveo's drugs is approved in the United States for the treatment of adults with connective tissue tumors. The headquarters is located in Stamford, Connecticut.

Merck unit SpringWorks has claimed EU approval for Ogsiveo, becoming the first approved therapy for desmoid tumours in Europe.

The collaboration will explore RNA-based small molecule drug candidates aimed at neurological conditions where existing ...